New AMR certification launched for antibiotic manufacturers

Xin Weisheng

Home > News > INDUSTRY NEWS >

06 Jun 2023
New AMR certification launched for antibiotic manufacturers

Following publication of the Antibiotic Manufacturing Standard in 2022 to help overcome AMR, antibiotic manufacturers can now verify their actions through a new certification.


A new global Minimized Risk of Antimicrobial Resistance (AMR) certification has been launched to promote and demonstrate responsible antibiotic manufacturing in the global pharmaceutical supply chain.


BSI, a UK standards body, developed the new certification to the Antibiotic Manufacturing Standard published in June 2022.


Following this “ground-breaking standard” stated Courtney Soulsby, BSI Global Director for Healthcare Sustainability, the certification will “promote responsible pharmaceutical manufacturing and help protect the natural environment and slow antimicrobial resistance”.


Being certified facilitates independent third-party verification that waste streams containing antibiotic active pharmaceutical ingredient (API) and drug products are appropriately controlled during manufacturing by pharmaceutical companies.


How will the Antimicrobial Resistance certification work?


The certification programme will involve initial evaluation against the requirements of the standard plus annual surveillance to verify ongoing maintenance of the appropriate controls over time.


After initial launch, all antibiotic manufacturers globally will be eligible to obtain the certification.


Big Pharma companies are seeking to have independent evidence of their compliance to the Antibiotic Manufacturing Standard for a selection of their antibiotics as first market achievers that participated in a pilot programme. These include Pfizer, Roche, Sandoz and Teva.


“Pfizer was delighted to participate in the pilot [scheme] for this new certification programme to help ensure appropriate control of antimicrobial manufacturing waste, and looks forward to its adoption across the pharmaceutical industry,” stated Dermot Dolan, Internal Audit & Supplier Operations EHS Lead at Pfizer.


As well as the partnership between BSI and the AMR Industry Alliance, companies involved in the pilot have offered their support in reviewing the development of the technical assessment process and expressed interest in participating in the certification themselves, as well as strongly encouraging their supply chain partners to do so.


According to the World Health Organization (WHO), AMR is one of the top 10 global public health threats, with scientists estimating there were an estimated total 4.95 million deaths associated with bacterial AMR in 2019. The UN Environment Programme (UNEP) recently published an in-depth report, concluding that “the environment plays a key role in the development, transmission and spread of AMR.”


(Source: EPR)

  • wechat
Recent Posts
  • Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    22 Oct 2024
    Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
    Find out more
  • Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    20 Sep 2024
    Just – Evotec Biologics Opens Its First J.POD Facility in Europe
    Find out more
  • AI biotechs Exscientia and Recursion agree $688m merger
    12 Aug 2024
    AI biotechs Exscientia and Recursion agree $688m merger
    Find out more

WANT TO KNOW MORE ABOUT HOW OUR

SOLUTIONS CAN HELP YOU?

Cookies
Our site uses cookies. We’d also like to set optional cookies to give you the best experience and porvide you relevant advertising. You can choose to manage your preferences or accept all cookies. You can also read our Privacy Policy and Cookie Policy for more information.